List view / Grid view
Here, EPR explores some highlights of the UK’s new Life Sciences Vision for the pharma, biopharma and biotech industries, covering topics from funding to regulatory reviews and clinical trial innovation.
Eli Lilly and Company have announced executive leadership changes and the creation of neuroscience and immunology business units.
In a Phase II trial, Leukine® (sargramostim) significantly reduced biomarkers of neurodegeneration and improved cognitive function.
Treatment with XPro1595 for three months caused significant changes in neurodegeneration, synaptic function and neuroinflammation.
Scientists have found a way to effectively transport medication into the brain which could lead to improved treatments for neurological and neurodegenerative diseases.
21 February 2011 | By Roche
Role will focus on disorders such as schizophrenia, neurodegeneration, treatment-resistant depression & neurodevelopment...